Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC12222Pexidartinib (PLX3397)CAS: 1029044-16-3纯度: >98.00%
Pexidartinib(PLX3397) 是一种口服小分子酪氨酸激酶抑制剂,对集落刺激因子 1(CSF1) 受体 (IC50=20nM)、KIT 原癌基因受体酪氨酸激酶 (KIT)(IC50 = 10nM) 和类 FMS 酪氨酸激酶 3Pexidartinib 在体外是一种比伊马替尼更强的 KIT 抑制剂。
- GC12247K-Ras(G12C) inhibitor 12CAS: 1469337-95-8纯度: >98.00%
An allosteric inhibitor of oncogenic K-Ras(G12C)
- GC12257Panobinostat (LBH589)CAS: 404950-80-7纯度: >99.00%
Panobinostat (LBH589)是一种强效,且具有口服活性和抗肿瘤活性的广谱组蛋白去乙酰化酶(HDAC)抑制剂,IC 50 值为5nM。
- GC12308Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) DisodiumCAS: 168555-66-6纯度: >99.00%
Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium是一种微管解聚药物,作为Combretastatin A4(CA4)的水溶性前体药物。
- GC12353Mitomycin CCAS: 50-07-7纯度: >98.00%
Mitomycin C是一种抗生素,从链霉菌(Streptomyces Caespitosus)或淡紫色链霉菌(Streptomyces Lavendulae)中分离出来。
- GC12387Tiplaxtinin(PAI-039)CAS: 393105-53-8纯度: >98.00%
Tiplaxtinin(PAI-039)是一种口服生物利用的尿激酶型纤溶酶原激活物抑制剂-1(PAI-1)拮抗剂,IC 50 值为2.7μM。
- GC12391XanthohumolCAS: 6754-58-1纯度: >99.50% / >98.00%
Xanthohumol是啤酒花中主要的异戊烯基黄酮类化合物,能够抑制二酰甘油酰基转移酶(DGAT),IC 50 值为50.3μM。
- GC12415RigosertibCAS: 592542-59-1纯度: >98.50%
Rigosertib (ON-01910) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3 激酶/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。
- GC12426Birinapant (TL32711)CAS: 1260251-31-7纯度: >99.50%
Birinapant (TL32711) 是一种 SMAC 模拟物,旨在专门针对 cIAP1 和 cIAP2 进行降解。
- GC12515NMS-1286937CAS: 1034616-18-6纯度: >99.00% / >98.00%
NMS-1286937是一种口服有效的小分子化合物,能够高效且选择性地抑制Polo样激酶1(PLK1)的活性,半数抑制浓度(IC 50 )为2nM。
- GC12555GS-9620 (Vesatolimod)CAS: 1228585-88-3纯度: >99.50%
GS-9620 (Vesatolimod)是一种具口服活性的有效的Toll样受体7(TLR7)激动剂,EC 50 值为291nM,具有抗病毒作用。
- GC12573Temsirolimus (CCI-779)CAS: 162635-04-3纯度: >99.50%
Temsirolimus (CCI-779)是雷帕霉素的酯类衍生物,可抑制mTOR激酶活性,IC 50 值为1.76 ± 0.15μM。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC12199 | MI-3 | 1271738-59-0 | >98.00% | |
An inhibitor of menin-MLL fusion protein interactions | ||||
| GC12222 | Pexidartinib (PLX3397) | 1029044-16-3 | >98.00% | |
Pexidartinib(PLX3397) 是一种口服小分子酪氨酸激酶抑制剂,对集落刺激因子 1(CSF1) 受体 (IC50=20nM)、KIT 原癌基因受体酪氨酸激酶 (KIT)(IC50 = 10nM) 和类 FMS 酪氨酸激酶 3Pexidartinib 在体外是一种比伊马替尼更强的 KIT 抑制剂。 | ||||
| GC12223 | Z-Asp-CH2-DCB | 153088-73-4 | >99.00% | |
A pan-caspase inhibitor | ||||
| GC12247 | K-Ras(G12C) inhibitor 12 | 1469337-95-8 | >98.00% | |
An allosteric inhibitor of oncogenic K-Ras(G12C) | ||||
| GC12256 | D-Mannitol | 69-65-8 | >99.00% | |
An Analytical Reference Standard | ||||
| GC12257 | Panobinostat (LBH589) | 404950-80-7 | >99.00% | |
Panobinostat (LBH589)是一种强效,且具有口服活性和抗肿瘤活性的广谱组蛋白去乙酰化酶(HDAC)抑制剂,IC 50 值为5nM。 | ||||
| GC12308 | Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium | 168555-66-6 | >99.00% | |
Fosbretabulin (Combretastatin A4 Phosphate (CA4P)) Disodium是一种微管解聚药物,作为Combretastatin A4(CA4)的水溶性前体药物。 | ||||
| GC12318 | Candesartan Cilexetil | 145040-37-5 | >99.50% | |
A prodrug form of candesartan | ||||
| GC12332 | NU 7026 | 154447-35-5 | >99.50% | |
Inhibitor of DNA-dependent protein kinase | ||||
| GC12337 | Tenovin-3 | 1011301-27-1 | >99.50% | |
A small molecule activator of p53 | ||||
| GC12348 | Ro 3306 | 872573-93-8 | >98.00% | |
Ro 3306是一种ATP竞争性抑制剂,主要靶向CDK1/cyclin B1(K i 值为35nmol/L)和CDK1/cyclin A复合物(K i 值为110nmol/L)。 | ||||
| GC12353 | Mitomycin C | 50-07-7 | >98.00% | |
Mitomycin C是一种抗生素,从链霉菌(Streptomyces Caespitosus)或淡紫色链霉菌(Streptomyces Lavendulae)中分离出来。 | ||||
| GC12367 | CM-272 | 1846570-31-7 | >98.00% | |
An inhibitor of G9a, GLP, and DNA methyltransferases | ||||
| GC12375 | PF-4989216 | 1276553-09-3 | >99.50% | |
An orally bioavailable PI3K inhibitor | ||||
| GC12387 | Tiplaxtinin(PAI-039) | 393105-53-8 | >98.00% | |
Tiplaxtinin(PAI-039)是一种口服生物利用的尿激酶型纤溶酶原激活物抑制剂-1(PAI-1)拮抗剂,IC 50 值为2.7μM。 | ||||
| GC12391 | Xanthohumol | 6754-58-1 | >99.50% / >98.00% | |
Xanthohumol是啤酒花中主要的异戊烯基黄酮类化合物,能够抑制二酰甘油酰基转移酶(DGAT),IC 50 值为50.3μM。 | ||||
| GC12415 | Rigosertib | 592542-59-1 | >98.50% | |
Rigosertib (ON-01910) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3 激酶/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。 | ||||
| GC12426 | Birinapant (TL32711) | 1260251-31-7 | >99.50% | |
Birinapant (TL32711) 是一种 SMAC 模拟物,旨在专门针对 cIAP1 和 cIAP2 进行降解。 | ||||
| GC12450 | BI 2536 | 755038-02-9 | >99.50% / >98.00% | |
BI 2536是一种双重Polo样激酶(PLK)/溴结构域抑制剂,在无细胞激酶实验中,BI 2536 对PLK1、PLK2和PLK3的半数抑制浓度(IC 50 )值分别为0.83nM、3.5nM和9.0nM。 | ||||
| GC12515 | NMS-1286937 | 1034616-18-6 | >99.00% / >98.00% | |
NMS-1286937是一种口服有效的小分子化合物,能够高效且选择性地抑制Polo样激酶1(PLK1)的活性,半数抑制浓度(IC 50 )为2nM。 | ||||
| GC12531 | Cabozantinib malate (XL184) | 1140909-48-3 | >99.50% | |
A VEGFR2 inhibitor | ||||
| GC12545 | 2-HBA | 131359-24-5 | >98.00% | |
An indirect inhibitor of Keap1-Nrf2 interactions | ||||
| GC12555 | GS-9620 (Vesatolimod) | 1228585-88-3 | >99.50% | |
GS-9620 (Vesatolimod)是一种具口服活性的有效的Toll样受体7(TLR7)激动剂,EC 50 值为291nM,具有抗病毒作用。 | ||||
| GC12573 | Temsirolimus (CCI-779) | 162635-04-3 | >99.50% | |
Temsirolimus (CCI-779)是雷帕霉素的酯类衍生物,可抑制mTOR激酶活性,IC 50 值为1.76 ± 0.15μM。 | ||||
